Journal
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH
Volume 14, Issue 2, Pages 182-195Publisher
KOREAN ACAD ASTHMA ALLERGY & CLINICAL IMMUNOLOGY
DOI: 10.4168/aair.2022.14.2.182
Keywords
Exacerbation; forced expiratory volume; quality of life; randomized controlled trial; asthma; biological products
Categories
Funding
- Sanofi
- Regeneron Pharmaceuticals, Inc.
Ask authors/readers for more resources
In Korean patients, dupilumab treatment reduced annualized severe exacerbation rates, improved FEV1, asthma control, and quality of life, while decreasing inflammatory biomarkers levels. The incidence of adverse events was comparable between the dupilumab and placebo group.
Purpose: To assess the effect of dupilumab on the annualized severe exacerbation rates, change in forced expiratory volume at first second (FEV1), overall asthma control and health-related quality of life in Korean patients from the LIBERTY ASTHMA QUEST study. Methods: Of the 1,902 patients enrolled in the LIBERTY ASTHMA QUEST study, a phase-3, randomized, double-blind, placebo-controlled, parallel-group study on dupilumab, 74 (4%) were Korean. The patients were randomly assigned to 4 treatment groups (2:2:1:1). The sub-analysis reported herewith was performed with the pooled groups of dupilumab and placebo from the 4 original treatment groups in the LIBERTY ASTHMA QUEST study. The efficacy endpoints were annualized rate of severe exacerbation events during the 52-week study period and changes from baseline in pre-bronchodilator FEV1 in week 12. Asthma control, asthma quality of life and the effect of treatment on the levels of type 2 inflammatory biomarkers were assessed. The safety profile was also evaluated. Results: In Korean patients, annualized severe exacerbation rates were reduced with dupilumab (n = 49) compared to placebo (n = 25) (0.259 vs 1.942) during the 52-week treatment period. The relative risk reduction with dupilumab was 87% (P< 0.001). Improvements in pre-bronchodilator FEV1 (mean difference of 0.24 L, P = 0.021) were observed in week 12 in dupilumab-treated patients. Additionally, improvements in asthma control and asthma-related quality of life were observed; the FeNO and serum immunoglobulin E levels were reduced. The incidence of adverse events and serious adverse events was comparable between the dupilumab and placebo group. A total of 11 patients from the dupilumab group reported 63 injection site reactions. Conclusions: Dupilumab, as an add-on therapy in severe asthma, is efficacious and has an acceptable safety profile in Korean patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available